Warner Douglas J 4

What Happened
Douglas J. Warner, Chief Medical Officer of Tyra Biosciences (TYRA), was granted a total of 110,000 restricted stock units (RSUs) on May 5, 2026 — reported as 25,000 shares (acquired) and 85,000 derivative RSUs (acquired) at $0.00 per share. These are awards (transaction code A), so no cash was exchanged at grant; each RSU represents a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date: May 5, 2026; Form 4 filed May 7, 2026 (timely filing).
• Grant amounts: 25,000 RSUs + 85,000 RSUs = 110,000 RSUs granted; grant price reported $0.00.
• Vesting (per footnotes): 1/4 of the RSUs vest on each of the first four anniversaries of May 5, 2026, subject to continued service (F1). Footnote F2 indicates the reported derivative amount includes RSUs. Footnote F3 references a separate option vesting schedule (1/48th monthly after May 5, 2026) if applicable.
• Shares owned after the transaction: Not specified in the filing.

Context
RSU grants are compensation awards that convert to shares only after vesting and continuous service; they are not an immediate open‑market purchase or sale. Because these were awards, they do not directly indicate buying or selling sentiment—rather, they reflect equity compensation. The filing shows no cash paid and no immediate sale of underlying shares.